

August 22, 2022

**BSE Limited**  
Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
Scrip Code: 524742

**National Stock Exchange of India Ltd.,**  
Department of Corporate Services  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

**Sub: Press Release - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We enclose a Press Release regarding " Caplin Point listed on Forbes Asia's "200 Best Under a Billion" for 2022 for dissemination.

Kindly take the same on record.

Thanking You,

Sincerely Yours  
**For Caplin Point Laboratories Limited**

  
Venkatram G  
**General Counsel and Company Secretary**

Encl: A/a



**Press Release**

**For immediate release**

**Caplin Point listed on Forbes Asia’s “200 Best Under a Billion” for 2022**

Caplin Point Laboratories Ltd has been selected under Forbes Asia’s 200 Best Under a Billion list for 2022. Forbes Asia has selected 200 best performing companies, with revenues of less than a billion, from a list of over 17,000 public listed companies across the Asia-Pacific.

“This is the 5<sup>th</sup> time in the last 9 years that we’ve been featured on this prestigious list and is unprecedented for an Indian Pharmaceutical company. We aim for excellence across all aspects of our growth, with a razor sharp focus towards benchmark cashflows and profitability, and this listing is a testament to that.” said Mr.C.C.Paarthipan, Chairman, Caplin Point Laboratories, on the listing.

Caplin Point has also been ranked #1 in India for “Most Consistent Profitable Growth across last 10 years” by Value Research magazine in the Wealth Insight June 2022 issue.

**ABOUT CAPLIN POINT LABORATORIES LIMITED**

Caplin Point Laboratories Limited is a fast-growing pharmaceutical Company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company’s Subsidiary Caplin Steriles Limited caters to the Regulated Markets for Injectable and Ophthalmic products.

Caplin Point Laboratories Limited has been selected on Forbes Asia’s “200 Best Under a Billion” list 5 times in the last 9 years (2014, 2015, 2016, 2021 and 2022), and was recently awarded “The Emerging Company of 2018” and “Business Excellence Award for 2019” by Economic Times.

**Cautionary Statement:**

*This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no*



*obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.*

For details, please contact:

<b>Investor Relations at Caplin</b> Mr. G Venkatram (General Counsel & Company Secretary) Tel: +91 44 24968000 <a href="mailto:investor@caplinpoint.net">investor@caplinpoint.net</a>	<b>Registered Office</b> 3 <sup>rd</sup> Floor, Ashvich Towers, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai – 600 096, Tamil Nadu, INDIA. Tel : +91 44 2496 8000 CIN: L24231TN1990PLC019053 ISIN: INE475E01026 NSE Code: CAPLIPOINT BSE CODE: 524742 Website: <a href="http://www.caplinpoint.net">www.caplinpoint.net</a>
---	--